Zentralbl Chir 2011; 136(1): 11-17
DOI: 10.1055/s-0030-1262603
Übersicht

© Georg Thieme Verlag KG Stuttgart ˙ New York

Sekundäre Peritonitis

Secondary PeritonitisW. Hartl1 , D. Kuppinger1 , M. Vilsmaier1
  • 1Chirurgische Klinik, Universität Campus Großhadern LMU München, München, Deutschland
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. Februar 2011 (online)

Zusammenfassung

Hintergrund: Bis heute ist nicht genau bekannt, in wieweit chirurgische bzw. intensivmedizinische Determinanten für die Prognose von Patienten mit intensivpflichtiger sekundärer Peritonitis und ­konsekutivem Organversagen relevant sind. Ferner ist unklar, ob sich die Prognose dieser ­Patienten seit 2002 durch die Einführung neuer intensiv­medizinischer Therapien („Surviving Sepsis Campaign“) verbessert hat. Material und Methodik: MEDLINE, EMBASE und Cochrane-Datenbanken wurden anhand der Stichwörter „source control“, „peritonitis“, „operation“, critical care“ und „antibiotics“ nichtsystematisch nach Publikationen durchsucht, die zwischen 1985 und 2010 erschienen waren. Wir berichten auch über Erfahrungen bei entsprechenden Hochrisikopatienten aus unserer eigenen Klinik. Ergebnisse: Sowohl eine fehlende Fokuskontrolle als auch eine inadäquate empirische antimikro­bielle Therapie verschlechtert die Akutprognose. In Abhängigkeit vom initialen Befund sind die programmierte Lavage und die „On-demand“-Relaparotomie sich ergänzende Konzepte. Die prognostische Bedeutung der Zahl der Revisionseingriffe ist bisher ungeklärt. Eine Behandlung nach 2002 ist mit einer deutlich besseren Akutprognose verbunden. Im Gegensatz zur Fokuskontrolle sind die Mechanismen, durch die sich bei inadäquater empirischer antimik­robieller Therapie die Letalität erhöht, unklar. Schlussfolgerung: Die Fokuskontrolle ist die wichtigste Determinante der Akutletalität und muss deswegen in der klinisch-therapeutischen Hierarchie an erster Stelle stehen. Die Zahl der zur Fokuskontrolle nötigen Revisionseingriffe kann nicht als Entscheidungshilfe bez. Fortführung oder Abbruch der Therapie herangezogen werden. Die Verbesserung der Prognose in den letzten Jahren bestätigt die Effizienz neuer intensivmedizinischer Thera­pien bei diesem Hochrisikokollektiv auch im klinischen Alltag. 

Abstract

Background: There is some controversy regarding concepts currently propagated for an optimal surgical and antibiotic therapy in patients with sec­ondary peritonitis and organ failure. It is not known whether the recent general progress in criti­cal care (“Surviving Sepsis Campaign”) has also improved outcome of this particular patient group. Methods: MEDLINE, EMBASE and Cochrane databases were non-systematically searched from 1985 through January 2010 using the words “source control”, “peritonitis”, “operation”, “critical care” and “antibiotics”. We also present experiences in corresponding high risk patients from our institution. Results: The inability to obtain source control and an inadequate initial antibiotic therapy were ­associated with a clearly higher mortality. De­pending on the initial intraoperative finding, planned and on demand relaparotomy do not conflict, but complement one another. The importance of the number of surgical revisions remains to be determined. Treatment after 2002 was associated with an improved prognosis. In contrast to source control, the mechanisms of increasing mortality with an inadequate initial antibiotic therapy remain controversial. Conclusion: Source control is the most important determinant for acute survival and has to be placed on top of the therapeutic priority list. The number of revisions needed to obtain source control, however, does not vary with survival and cannot guide decisions on therapy withdrawal or continuation. The recent prognostic improvement indicates the efficiency of new adjuvant therapeutic measures in unselected surgical high-risk patients. 

Literatur

  • 1 Calandra T, Cohen J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit.  Crit Care Med. 2005;  33 1538-1548
  • 2 Nathens A B, Rotstein O D, Marshall J C. Tertiary peritonitis: clinical features of a complex nosocomial infection.  World J Surg. 1998;  22 158-163
  • 3 Van Ruler O, Lamme B, Gouma D J et al. Variables associated with positive findings at relaparotomy in patients with secondary peritonitis.  Crit Care Med. 2007;  35 468-476
  • 4 Pacelli F, Doglietto G B, Alfieri S et al. Prognosis in intraabdominal infections. Multivariate analysis on 604 patients.  Arch Surg. 1996;  131 641-645
  • 5 Mosdell D M, Morris D M, Voltura A et al. Antibiotic treatment for surgical peritonitis.  Ann Surg. 1991;  214 543-549
  • 6 Montravers P, Chalfine A, Gauzit R et al. Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections.  Ann Surg. 2004;  239 409-416
  • 7 Thompson S K, Chang E Y, Jobe B A. Clinical review: Healing in gastro­intestinal anastomoses, part I.  Microsurgery. 2006;  26 131-136
  • 8 Vignali A, Fazio V W, Lavery I C et al. Factors associated with the occurrence of leaks in stapled rectal anastomoses: a review of 1 014 patients.  J Am Coll Surg. 1997;  185 105-113
  • 9 Alves A, Panis Y, Trancart D et al. Factors associated with clinically significant anastomotic leakage after large bowel resection: multivariate analysis of 707 patients.  World J Surg. 2002;  26 499-502
  • 10 Roehrborn A, Thomas L, Potreck O et al. The microbiology of postoperative peritonitis.  Clin Infect Dis. 2001;  33 1513-1519
  • 11 Montravers P, Gauzit R, Muller C et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy.  Clin Infect Dis. 1996;  23 486-494
  • 12 Barie P S, Vogel S B, Dellinger E P et al. A randomized, doubleblind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group.  Arch Surg. 1997;  132 1294-1302
  • 13 Farthmann E H, Schoffel U. Principles and limitations of operative management of intraabdominal infections.  World J Surg. 1990;  14 210-217
  • 14 Wacha H, Hau T, Dittmer R et al. Risk factors associated with intra­abdominal infections: a prospective multicenter study. Peritonitis Study Group.  Langenbecks Arch Surg. 1999;  384 24-32
  • 15 Schoeffel U, Jacobs E, Ruf G et al. Intraperitoneal micro-organisms and the severity of peritonitis.  Eur J Surg. 1995;  161 501-508
  • 16 Adkins A L, Robbins J, Villalba M et al. Open abdomen management of intra-abdominal sepsis.  Am Surg. 2004;  70 137-140
  • 17 Bohnen J, Boulanger M, Meakins J L et al. Prognosis in generalized peritonitis. Relation to cause and risk factors.  Arch Surg. 1983;  118 285-290
  • 18 Christou N v, Barie P S, Dellinger E P et al. Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome.  Arch Surg. 1993;  128 193-198
  • 19 Mulier S, Penninckx F, Verwaest C, Filez L et al. Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients.  World J Surg. 2003;  27 379-384
  • 20 Sotto A, Lefrant J Y, Fabbro-Peray P et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis.  J Antimicrob Chemother. 2002;  50 569-576
  • 21 Mosdell D M, Morris D M, Voltura A et al. Antibiotic treatment for surgical peritonitis.  Ann Surg. 1991;  214 543-549
  • 22 Schneider C P, Seyboth C, Vilsmaier M et al. Prognostic factors in critically ill patients suffering from secondary peritonitis: a retrospective, observational, survival time analysis.  World J Surg. 2009;  33 34-43
  • 23 Scheingraber S, Kurz T, Dralle H. Short- and long-term outcome and health-related quality of life after severe peritonitis.  World J Surg. 2002;  26 667-671
  • 24 Engel C, Brunkhorst F M, Bone H G et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study.  Intensive Care Med. 2007;  33 606-618
  • 25 Sakr Y, Reinhart K, Vincent J L et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study.  Crit Care Med. 2006;  34 589-597
  • 26 Kahn J M, Kramer A A, Rubenfeld G D. Transferring critically ill patients out of hospital improves the standardized mortality ratio: a simulation study.  Chest. 2007;  131 68-75
  • 27 Pieracci F M, Barie P S. Management of severe sepsis of abdominal origin.  Scand J Surg. 2007;  96 184-196
  • 28 Demetriades D, Constantinou C, Salim A et al. Liver cirrhosis in patients undergoing laparotomy for trauma: effect on outcomes.  J Am Coll Surg. 2004;  199 538-542
  • 29 Farnsworth N, Fagan S P, Berger D H et al. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients.  Am J Surg. 2004;  188 580-583
  • 30 Lamme B, Boermeester M A, Belt E J et al. Mortality and morbidity of planned relaparotomy versus relaparotomy on demand for secondary peritonitis.  Br J Surg. 2004;  91 1046-1054
  • 31 Beyersmann J, Wolkewitz M, Schumacher M. The impact of time-dependent bias in proportional hazards modelling.  Stat Med. 2008;  27 6439-6454
  • 32 Anaya D A, Nathens A B. Risk factors for severe sepsis in secondary peritonitis.  Surg Infect (Larchmt). 2003;  4 355-362
  • 33 Barie P S, Hydo L J, Eachempati S R. Longitudinal outcomes of intra-abdominal infection complicated by critical illness.  Surg Infect (Larchmt). 2004;  5 365-373
  • 34 Ochiai T, Hiranuma S, Takiguchi N et al. SOFA score predicts postoperative outcome of patients with colorectal perforation.  Hepatogastro­enterology. 2004;  51 1007-1010
  • 35 Gajic O, Urrutia L E, Sewani H et al. Acute abdomen in the medical ­intensive care unit.  Crit Care Med. 2002;  30 1187-1190
  • 36 Barie P S, Williams M D, McCollam J S et al. PROWESS Surgical Evaluation Committee. Benefit / risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.  Am J Surg. 2004;  188 212-220
  • 37 Riché F C, Dray X, Laisné M J et al. Factors associated with septic shock and mortality in generalized peritonitis: comparison between community-acquired and postoperative peritonitis.  Crit Care. 2009;  13 R9938
  • 38 Olak J, Christou N V, Stein L A et al. Operative vs percutaneous drainage of intra-abdominal abscesses. Comparison of morbidity and mortality.  Arch Surg. 1986;  121 141-146
  • 39 Hemming A, Davis N L, Robins R E. Surgical versus percutaneous drainage of intra-abdominal abscesses.  Am J Surg. 1991;  161 593-595
  • 40 Bufalari A, Giustozzi G, Moggi L. Postoperative intraabdominal abscesses: percutaneous versus surgical treatment.  Acta Chir Belg. 1996;  96 197-200
  • 41 Kok K Y, Yapp S K. Laparoscopic drainage of postoperative complicated intra-abdominal abscesses.  Surg Laparosc Endosc Percutan Tech. 2000;  10 311-313
  • 42 Koperna T, Schulz F. Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection.  World J Surg. 2000;  24 32-37
  • 43 Garcia-Sabrido J L, Tallado J M, Christou N V et al. Treatment of severe ­intra-abdominal sepsis and / or necrotic foci by an “open-abdomen” approach. Zipper and zipper-mesh techniques.  Arch Surg. 1988;  123 152-156
  • 44 Wittmann D H, Aprahamian C, Bergstein J M. Etappenlavage: advanced diffuse peritonitis managed by planned multiple laparotomies utilizing zippers, slide fastener, and Velcro analogue for temporary abdominal closure.  World J Surg. 1990;  14 218-226
  • 45 Hinck D, Struve R, Gatzka F et al. Vacuum-assisted fascial closure in the management of diffuse peritonitis.  Zentralbl Chir. 2006;  131 Suppl 1 108-110
  • 46 Mughal M M, Bancewicz J, Irving M H. ‘Laparostomy’: a technique for the management of intractable intra-abdominal sepsis.  Br J Surg. 1986;  73 253-259
  • 47 Cheatham M L, Safcsak K, Brzezinski S J et al. Nitrogen balance, protein loss, and the open abdomen.  Crit Care Med. 2007;  35 127-131
  • 48 Van Goor H, Hulsebos R G, Bleichrodt R P. Complications of planned re­laparotomy in patients with severe general peritonitis.  Eur J Surg. 1997;  163 61-66
  • 49 Sautner T, Gotzinger P, Redl-Wenzl E M et al. Does reoperation for abdominal sepsis enhance the inflammatory host response?.  Arch Surg. 1997;  132 250-255
  • 50 Bunt T J. Urgent relaparotomy: the high-risk, no-choice operation.  Surgery. 1985;  98 555-560
  • 51 Bunt T J. Non-directed relaparotomy for intra-abdominal sepsis. A futile procedure.  Am Surg. 1986;  52 294-298
  • 52 Hinsdale J G, Jaffe B M. Re-operation for intra-abdominal sepsis. Indications and results in modern critical care setting.  Ann Surg. 1984;  199 31-36
  • 53 Merlino J I, Yowler C J, Malangoni M A. Nosocomial infections adversely affect the outcomes of patients with serious intraabdominal infections.  Surg Infect. 2004;  5 21-27
  • 54 Schein M. Planned reoperations and open management in critical ­intra-abdominal infections: prospective experience in 52 cases.  World J Surg. 1991;  15 537-545
  • 55 Rakic M, Popovic D, Rakic M et al. Comparison of on-demand vs planned relaparotomy for treatment of severe intraabdominal infections.  Croat Med J. 2005;  46 957-963
  • 56 Hau T, Ohmann C, Wolmershauser A et al. Planned relaparotomy vs relaparotomy on demand in the treatment of intraabdominal infections. The Peritonitis Study Group of the Surgical Infection Society-Europe.  Arch Surg. 1995;  130 1193-1196
  • 57 Van Ruler O, Mahler C W, Boer K R et al. Dutch Peritonitis Study Group. Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis: a randomized trial.  JAMA. 2007;  298 865-872
  • 58 Rau B, Pralle U, Mayer J M et al. Role of ultrasonographically guided fine-needle aspiration cytology in the diagnosis of infected pancreatic necrosis.  Br J Surg. 1998;  85 179-184
  • 59 Berger D, Buttenschoen K. Management of abdominal sepsis.  Langenbecks Arch Surg. 1998;  383 35-43
  • 60 Brooks G, Butel J, Morse S. Jawetz, Melnick & Adelberg’s Medical Microbiology. Stamford: Appleton & Lange, 1998
  • 61 Tellado J M. The need for new antimicrobials for intra-abdominal infections (IAI): defining the forthcoming scenario.  Surg Infect. 2006;  7 1-4
  • 62 Dela Pena A S, Asperger W, Kockerling F et al. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.  J Gastrointest Surg. 2006;  10 567-574
  • 63 Thadepalli H, Gorbach S L, Broido P W et al. Abdominal trauma, anaerobes, and antibiotics.  Surg Gynecol Obstet. 1973;  137 270-276
  • 64 Berne T V, Yellin A E, Appleman M D et al. Surgically treated gangrenous or perforated appendicitis. A comparison of aztreonam and clinda­mycin versus gentamicin and clindamycin.  Ann Surg. 1987;  205 133-137
  • 65 Sitges-Serra A, Lopez M J, Girvent M et al. Postoperative enterococcal infection after treatment of complicated intraabdominal sepsis.  Br J Surg. 2002;  89 361-367
  • 66 Peoples J B. Candida and perforated peptic ulcers.  Surgery. 1986;  100 758-764
  • 67 Dupont H, Bourichon A, Paugam-Burtz C et al. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis?.  Crit Care Med. 2003;  31 752-757
  • 68 Montravers P, Dupont H, Gauzit R et al. Candida as a risk factor for mortality in peritonitis.  Crit Care Med. 2006;  34 646-652
  • 69 Dupont H, Paugam-Burtz C, Muller-Serieys C et al. Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients.  Arch Surg. 2002;  137 1341-1346
  • 70 Bodmann K F und die Expertenkommission der Infektliga. Komplizierte intraabdominelle Infektionen: Erreger, Resistenzen. Empfehlungen der Infektliga zur Antibiotikatherapie.  Chirurg. 2010;  81 38-49
  • 71 Solomkin J S, Mazuski J E, Bradley J S et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases ­Society of America.  Surg Infect (Larchmt). 2010;  11 79-109
  • 72 Micek S T, Roubinian N, Heuring T et al. Before-after study of a standardized hospital order set for the management of septic shock.  Crit Care Med. 2006;  34 2707-2713
  • 73 Kollef M H, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.  Chest. 1999;  115 462-474
  • 74 Krobot K, Yin D, Zhang Q et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery.  Eur J Clin Microbiol Infect Dis. 2004;  23 682-687
  • 75 Sturkenboom M C, Goettsch W G, Picelli G et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs.  Br J Clin Pharmacol. 2005;  60 438-443
  • 76 Kollef M H, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia.  Chest. 1998;  113 412-420
  • 77 Rello J, Gallego M, Mariscal D et al. The value of routine microbial investigation in ventilator-associated pneumonia.  Am J Respir Crit Care Med. 1997;  156 196-200
  • 78 Marshall J C, Innes M. Intensive care unit management of intra-abdominal infection.  Crit Care Med. 2003;  31 2228-2237
  • 79 Boos C, Kujath P, Bruch H P. Intraabdominelle Pilzinfektionen.  Mycoses.. 2005;  48 Suppl 1 22-26
  • 80 Dellinger R P, Carlet J M, Masur H et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.  Crit Care Med. 2004;  32 858-873
  • 81 Laterre P F, Levy H, Clermont G et al. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.  Crit Care Med. 2004;  32 2207-2218
  • 82 Vincent J L, Bernard G R, Beale R et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.  Crit Care Med. 2005;  33 2266-2277

Prof. W. Hartl

Chirurgische Klinik der Universität · Campus Großhadern · LMU München

Marchioninistr. 15

D-81377 München

Deutschland

Telefon: 00 49 / 89 / 70 95 55 53

Fax: 00 49 / 89 / 70 95 54 59

eMail: whartl@med.uni-muenchen.de